Michael W. Kalb

Michael brings more than 30 years of experience in the pharmaceutical and financial service industries. He most recently served as the Executive Vice President & Chief Financial Officer of CinCor Pharma, Inc., a publicly traded biotechnology company, where he played an integral role in the company’s recent acquisition by AstraZeneca for up to $1.8 billion. Previously, Michael served as Senior Vice President & Chief Financial Officer of Amarin Corporation plc from June 2016 through June 2022 where he contributed to significant revenue growth and led multiple financing rounds. Prior to joining Amarin, he was Group Vice President & Chief Financial Officer of Taro Pharmaceuticals Industries, Ltd.

Before beginning his tenure in the pharmaceutical sector, Michael held roles of increasing seniority and responsibility at accounting and consulting firms including Huron Consulting Group, Inc. and Ernst & Young LLP, where he began his career. He received a B.S. in Business Administration from the State University of New York, University at Albany, School of Business.